Cagrilintide
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk · Phase 1 · Completed · Enrollment 178
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part A: NNC0174-1213 (SD1-SD5) | n/r | n/r | n/r | n/r |
| Part A: Cagrilintide (SDA and SDB) | n/r | n/r | n/r | n/r |
| Part A: Placebo | n/r | n/r | n/r | n/r |
| Part B: NNC0174-1213 (MD1-MD5) | n/r | n/r | n/r | n/r |
| Part B: Cagrilintide (MDA) | n/r | n/r | n/r | n/r |
| Part B: Placebo | n/r | n/r | n/r | n/r |
Not shown
- Part A: NNC0174-1213 (SD1-SD5): endpoint not reported
- Part A: Cagrilintide (SDA and SDB): endpoint not reported
- Part A: Placebo: endpoint not reported
- Part B: NNC0174-1213 (MD1-MD5): endpoint not reported
- Part B: Cagrilintide (MDA): endpoint not reported
- Part B: Placebo: endpoint not reported